Sone Capital Management LLC Acquires New Position in Definitive Healthcare Corp. (NASDAQ:DH)

Sone Capital Management LLC acquired a new position in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 231,760 shares of the company's stock, valued at approximately $953,000. Sone Capital Management LLC owned 0.20% of Definitive Healthcare at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Nisa Investment Advisors LLC grew its stake in shares of Definitive Healthcare by 3,652.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock worth $29,000 after purchasing an additional 6,794 shares in the last quarter. Bayesian Capital Management LP acquired a new position in shares of Definitive Healthcare during the fourth quarter worth $41,000. Ieq Capital LLC acquired a new position in shares of Definitive Healthcare during the fourth quarter worth $51,000. KLP Kapitalforvaltning AS acquired a new position in shares of Definitive Healthcare during the fourth quarter worth $54,000. Finally, Two Sigma Securities LLC acquired a new position in shares of Definitive Healthcare during the fourth quarter worth $56,000. Hedge funds and other institutional investors own 98.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DH. Barclays lowered their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a research note on Thursday. The Goldman Sachs Group boosted their target price on shares of Definitive Healthcare from $3.00 to $3.40 and gave the stock a "neutral" rating in a research note on Monday, May 12th. Finally, BTIG Research downgraded shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $5.10.

Definitive Healthcare Stock Performance

NASDAQ DH traded down $0.11 during trading hours on Friday, hitting $3.02. The company had a trading volume of 441,056 shares, compared to its average volume of 816,922. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare Corp. has a 1-year low of $2.15 and a 1-year high of $6.27. The company has a market cap of $448.90 million, a PE ratio of -0.97, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. The business has a 50 day moving average of $2.82 and a 200-day moving average of $3.81.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The business had revenue of $59.19 million during the quarter, compared to the consensus estimate of $56.20 million. During the same quarter in the prior year, the firm earned $0.08 earnings per share. The business's quarterly revenue was down 6.8% compared to the same quarter last year. As a group, equities research analysts expect that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.